Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

91 results about "Artery diseases" patented technology

Coronary artery disease, also called coronary heart disease, or simply, heart disease, affects millions of Americans. This serious condition is a result of plaque buildup in your arteries.

Systems, methods, and devices for image-based plaque analysis and risk determination

This application is directed to systems, methods, and devices for image based analysis of plaque. In some embodiments, the approaches herein can be used for developing treatment plans, which can include local treatment, systemic treatment, or both. In some embodiments, the approaches herein can be used for stent selection. In some embodiments, the approaches herein can be used for surgical planning, which can include robotic surgical planning. In some embodiments, the approaches herein can be used for image normalization. In some embodiments, the approaches herein can be used for identifying plaque calcification thresholds. In some embodiments, the approaches herein can be used for identifying thin cap fibroatheroma. In some embodiments, the approaches herein can be used for coronary artery tree reconstruction. Some embodiments are directed to coronary artery disease risk stratification.
Owner:CLEERLY INC

Systems, methods, and devices for image-based plaque analysis and risk determination

This application is directed to systems, methods, and devices for image based analysis of plaque. In some embodiments, the approaches herein can be used for developing treatment plans, which can include local treatment, systemic treatment, or both. In some embodiments, the approaches herein can be used for stent selection. In some embodiments, the approaches herein can be used for surgical planning, which can include robotic surgical planning. In some embodiments, the approaches herein can be used for image normalization. In some embodiments, the approaches herein can be used for identifying plaque calcification thresholds. In some embodiments, the approaches herein can be used for identifying thin cap fibroatheroma. In some embodiments, the approaches herein can be used for coronary artery tree reconstruction. Some embodiments are directed to coronary artery disease risk stratification.
Owner:CLEERLY INC

Chemical ablation and method of treatment for various diseases

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B
Owner:NEUROTRONIC INC

Polygenic risk score for coronary heart disease, construction method therefor, and application thereof in combination with clinical risk assessment

A polygenic risk score (PRS) for coronary artery disease, a construction method therefor, and an application thereof in combination with clinical risk assessment. The present invention first provides an application of a reagent for detecting individual information in preparation of a detection device for assessing the onset risk of the coronary artery disease, wherein the individual information comprises 311 CAD-related single nucleotide polymorphic sites, and the individual information preferably also comprises one or more of BP, BMI, DM, TC and Stroke-related single nucleotide polymorphic sites. The present invention further provides a method for constructing a comprehensive metaPRS for the coronary artery disease. In the present invention, the PRS and the conventional clinical risk factor score are further integrated, such that re-layering of the onset risk of the coronary artery disease can be realized. The present invention is of great significance to primary prevention of the coronary artery disease.
Owner:FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Coronary artery thrombectomy device and use method thereof

The invention discloses a coronary artery thrombectomy device and a use method thereof. The invention relates to an embolectomy device comprising an embolectomy head which is particularly designed to be deployable in a complex coronary artery system in order to optimally treat coronary artery diseases. The thrombector head may include a deployable framework having a plurality of branches that are in a closed state in a first position and an expanded state in a second position from which the framework expands radially away from the longitudinal axis, thereby enabling mechanical opening of an intravascular embolism pathway, and the operation can be repeated for multiple times in the folded state and the expanded state. The framework may include a capture protection net surrounding a distal end of the framework for capturing thrombus and fragments thereof. The thrombectomy device can be used for working in a straight and bent vascular system. In the thrombus removal process, the head of the thrombus extraction device can be inserted into the thrombus by using a proper guide wire; and then framework expansion is carried out to take out thrombus.
Owner:FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV

Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).
Owner:ARENA PHARMACEUTICALS INC

Application of super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.
Owner:NANTONG UNIV

Substituted hydantoinamides as ADAMTS7 antagonists

ActiveUS12398120B2Organic active ingredientsOrganic chemistryArterial Occlusive DiseasesArtery diseases
The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.
Owner:BAYER AG +1

Quinazoline dione compounds and their uses

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.
Owner:EDGEWISE THERAPEUTICS INC

Methods of treating coronary artery disease

PendingUS20250346683A1Antibody ingredientsCardiovascular disorderCoronary arteriesEndothelial lipase
This invention relates to methods of lowering plasma levels of endothelial lipase (EL) in patients in need thereof comprising administering MEDI5884 to subjects at a dose of from about 50 mg to about 600 mg per month.
Owner:MEDIMMUNE LLC

Stable oral pharmaceutical formulations

PCT designated stageWO2026143093A1Artery diseasesPharmaceutical medicine
The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.
Owner:METHOD PHARM LLC

Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: Pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis, atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
Owner:ARENA PHARMACEUTICALS INC

Sirna for inhibiting LPA gene expression, and modifier and use thereof

A siRNA for inhibiting LPA gene expression, and a modifier and the use thereof, belonging to the field of biomedicine. Provided are a double-stranded RNA molecule targeting an LPA gene, and a modifier thereof. Both in vivo and in vitro experiments show that the provided double-stranded RNA molecule can effectively inhibit LPA gene expression, and can be used for preventing and / or treating Lp(a)-related diseases, such as thrombosis, atherosclerotic thrombosis, coronary artery disease, ischemic strokes, aortic valve stenosis, heart failure, atrial fibrillation, and peripheral artery disease.
Owner:NANJING QIANYAN BIOTECH

INDIUM TIN OXIDE FILM COATED UPSTANDING SILICON NANOWIRES (ITO / USNWs) AND THE USE THEREOF IN SENSITIVE NANOELECTRONIC DEVICE (NED)

A nanostructural sensing substrate includes indium tin oxide (ITO) film coated upstanding silicon nanowires (ITO / USNWs). The ITO / USNWs are fabricated by coating an ITO film on USNWs, the density of which has been reduced using a facile Ag-assisted chemical etching method. Furthermore, the bioreceptor modified ITO / USNWs are developed to serve as the sensing substrate of the EGFETs device for label-free diagnosis of biomarker related diseases, such as Alzheimer's disease (AD), acute myocardial infarction, coronary artery disease (CAD), hepatic encephalopathy, lung fibrosis, Cushing's syndrome and cancers. The ITO-coated-USNWs are also used in nano-featured cell based biosensors (CBB) for electrically quantitative evaluation of drug release.
Owner:ETERNAL PI LTD

Coronary artery disease early risk prediction and typing method based on deep learning

The invention discloses a coronary artery disease early risk prediction and typing method based on deep learning, and belongs to the technical field of medical image processing. According to the method, cardiac angiography CTA image pixel-level segmentation is completed by using an image segmentation model, loss is optimized by using a medical image text feature fusion module and multi-modal feature alignment, and early risk prediction and typing of coronary artery diseases are completed. By introducing the multi-scale state space feature encoder, the hierarchical feature reconstruction module and the multi-modal feature alignment optimization loss module, efficient and accurate segmentation and risk assessment of the coronary artery CTA image are realized, a new technical means is provided for segmentation and risk assessment of the coronary artery CTA image, and the segmentation and risk assessment efficiency of the coronary artery CTA image is improved. The development of a multi-modal fusion technology in the field of medical image processing is promoted, powerful support is provided for early diagnosis, risk stratification and personalized treatment of coronary artery diseases, and the method has wide application prospects and important practical value.
Owner:JINLIN MEDICAL COLLEGE

Method and system for predicting coronary artery disease based on echocardiography

A method (100) for providing an analysis of coronary artery disease (CAD), comprising: (i) receiving (120) patient metadata regarding the patient; (ii) receiving (130) a time sequence of 2D and / or 3D ultrasound images of the patient's heart; (iii) selecting (140), by the CAD prediction system, a plurality of ultrasound images from the time series; (iv) processing (150) the selected plurality of ultrasound images using a trained AI algorithm of the CAD prediction system to generate a feature map of the selected plurality of ultrasound images; (v) analyzing (160) the generated feature map and the received patient metadata using a trained algorithm of the CAD prediction system to generate a CAD prediction output; (vi) providing (170) the generated CAD prediction output via a user interface of the CAD prediction system.
Owner:KONINKLIJKE PHILIPS NV

Methods of treatment of ANGPTL3 related diseases and disorders

Methods of treating diseases and conditions in human subjects in need thereof using pharmaceutical compositions comprising an ANGPTL3 RNAi agent are described, the treatment being partially mediated by reducing expression of the ANGPTL3 gene. When administered to a human subject in need thereof according to the methods disclosed herein, the disclosed pharmaceutical compositions comprising an ANGPTL3RNAi agent treat diseases and conditions associated with elevated triglyceride (TG) levels and / or elevated low density lipoprotein cholesterol (LDL-C), such as hypertriglyceridemia (including severe hypertriglyceridemia (SHTG)), homozygous familial hypercholesterolemia (HoFH), hypertriglyceridemia-induced pancreatitis, metabolic syndrome, obesity, hyperlipidemia, mixed dyslipidemia, abnormal lipid and / or cholesterol metabolism, atherosclerosis, cardiovascular disease, type II diabetes, coronary artery disease, and the like. The present invention relates to compounds of formula (I), in particular to compounds of formula (I), such as non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, heterozygous familial hypercholesterolemia (HeFH), statin-resistant hypercholesterolemia, other dyslipidemia, and other metabolism-related conditions and diseases.
Owner:ARROWHEAD PHARMACEUTICALS INC

New method for preparing oxopyridine compound, and key intermediate and use

A new route for preparing an oxopyridine compound as represented by formula (I) and a key intermediate thereof. The new route can greatly reduce the generation of isomer impurities, improve the selectivity of the reaction chirality and the selectivity of N / O-alkylation, increase the yield, avoid re-purification of a crude product, and reduce the cost, has a short production period, and is energy-saving and environmentally-friendly, and suitable for preparing a drug for treating and / or preventing diseases related to FXIa receptors, and particularly provides a new idea for preparing a drug for treating and / or preventing cerebrovascular artery diseases and / or peripheral artery diseases.
Owner:CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD

Inhibitor of aldose reductase

To provide an inhibitor of aldose reductase.SOLUTION: There are a new compound and its pharmaceutical composition, and various treatments of other disorders such as a method for promoting health aging of skin, treatment of dermopathy, treatment of cardiovascular disorder, treatment of nephropathy, treatment of angiogenic disorder such as cancer, treatment of tissue damage such as non-heat tissue damage, treatment of progressive myocardial infarction, treatment of ischemia damage, and treatment of complications caused by diabetes, which use the compound and the composition. The other damages are not limited to above, and can include atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, skin infectious disease, peripheral vascular disease, cerebral stroke, galactose blood disease, asthma, and PMM2-CDG.SELECTED DRAWING: None
Owner:APPLIED THERAPEUTICS INC

Quinazolindione compounds and their uses

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.
Owner:EDGEWISE THERAPEUTICS INC

Inhibitors of aldose reductase

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.
Owner:APPLIED THERAPEUTICS INC

Inhibitors of aldose reductase

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.
Owner:APPLIED THERAPEUTICS INC